Spectrum Of Activity
P. vivax malaria treatmentPrimaquine base 15-30 mg PO q24h x14dPrimaquine base 15 mg = Primaquine phosphate 26.3 mgNo data on renal dose adjustment
P. vivax malaria treatmentPrimaquine base 0.3 mg/kg PO q24h x14dPrimaquine base 15 mg = Primaquine phosphate 26.3 mgNo data on renal dose adjustment
Treatment for malaria
Perform G6PD deficiency testing prior to initiating treatment.
Obtain hematocrit and hemoglobin prior to initating treatment and at day 3 and 8 in patients with mild to moderate G6PD deficiency, unknown status, or where testing is unavailable.
Obtain blood cell counts and hemoglobin determinations in G6PD normal patients.
Closely observe patients with a previous idiosyncratic reaction to primaquine, history of hemolytic anemia, or nicotinamide adenine dinucleotide methemoglobin reductase deficiency.
Monitor EGC in patients with cardiac disease or with concomitant use of QT interval prolonging drugs.
- Carbamazepine- decreases activity
Levomethadyl- increased risk of cardiotoxicity
Aurothioglucose- increased risk of blood dyscrasias
Antimicrobial agent: Antimalarial agent, Aminoquinoline
Pregnancy category: C (국내 1등급)
Average serum half life: 3.7-9.6 hours
QT prolongation may occur, particularly with cardiac disease, or concomitant use of QT interval prolonging agents; monitoring recommended.
G6PD testing prior to initiation recommended.
Avoid pregnancy during treatment; negative pregnancy test required prior to treatment.